A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 423,800 shares of ANTX stock, worth $567,892. This represents 0.0% of its overall portfolio holdings.

Number of Shares
423,800
Previous 14,300 2863.64%
Holding current value
$567,892
Previous $30,000 1410.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.98 - $2.96 $401,310 - $1.21 Million
409,500 Added 2863.64%
423,800 $453,000
Q2 2024

Aug 09, 2024

BUY
$1.93 - $3.76 $27,599 - $53,768
14,300 New
14,300 $30,000
Q3 2022

Nov 14, 2022

SELL
$7.61 - $22.29 $28,157 - $82,473
-3,700 Reduced 14.4%
22,000 $382,000
Q2 2022

Aug 12, 2022

BUY
$7.7 - $18.82 $197,890 - $483,674
25,700 New
25,700 $199,000

Others Institutions Holding ANTX

About AN2 Therapeutics, Inc.


  • Ticker ANTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,402,700
  • Market Cap $26M
  • Description
  • AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...
More about ANTX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.